Walchandnagar Industries reported FY26 revenue of ₹296.26 crore. The company achieved a positive EBITDA of ₹35.49 crore, a significant turnaround from a negative EBITDA in the previous year. Net loss narrowed to ₹14.68 crore from ₹86.03 crore.
Walchandnagar Industries FY26 Results: Turnaround in Sight
Walchandnagar Industries reported for FY26 a total revenue of ₹296.26 crore and a positive EBITDA of ₹35.49 crore. The company reported a net loss of ₹14.68 crore for the fiscal year. Reader Takeaway: Positive EBITDA and narrowed losses signal recovery; NCLT case remains a key risk. ## What just happened Walchandnagar Industries announced its financial results for the fiscal year ending March 31, 2026. Revenue stood at ₹296.26 crore, a slight increase of 0.48% from ₹294.84 crore in FY25. The company achieved a positive EBITDA of ₹35.49 crore, a significant improvement from a negative EBITDA of ₹35.61 crore in the previous fiscal year. The net loss for FY26 narrowed substantially to ₹14.68 crore, down from ₹86.03 crore in FY25. ## Why this matters These results indicate a significant operational and financial turnaround for Walchandnagar Industries. The positive EBITDA and reduced net loss suggest improved profitability and cost management. The company also reported an order book of ₹871.77 crore, providing visibility for future revenue. ## The backstory The company's Satara plant experienced a lockout from March 2025 to November 2025, which has now been resolved. This operational disruption likely impacted previous periods. Walchandnagar Industries has been strategically focusing on the Defence, Nuclear, and Aerospace (DNA) sectors. ## What changes now With the resolution of the Satara plant lockout and a strategic focus on high-growth DNA sectors, the company is positioned to leverage its order book. The successful pivot towards Defence, Nuclear, and Aerospace is expected to drive future performance. ## Risks to watch A key risk is an application filed by an operational creditor under the Insolvency and Bankruptcy Code for a claim of approximately ₹7.95 crore. The matter is pending before the NCLT and has not been admitted. Additionally, various tax disputes are ongoing. ## Peer comparison As specific peer financial data for FY26 is not immediately available from the filing, a direct comparison is not feasible. However, the positive EBITDA trend is a crucial step in the company's recovery journey. ## Context metrics (time-bound) Export turnover significantly increased to ₹59.36 crore in FY26 from ₹9.61 crore in the prior year. Total expenses decreased to ₹310.25 crore in FY26 from ₹384.99 crore in FY25. ## What to track next Investors will be closely watching the resolution of the NCLT application and the company's ability to sustain its operational profitability and growth in the DNA sectors. Execution of the order book will be critical.
